Dr Peter Surman, Chief Scientific Officer at Douglas Pharmaceuticals based in West Auckland, talks about a new ketamine-based drug they are developing which in early trials is showing signs of successfully supporting people experiencing serious, treatment resistant depression. They are hopeful that this drug will become a viable alternative to ECT, and will eventually be widely available in Aotearoa New Zealand and overseas. With host Hamish Coleman-Ross and psychotherapist Kyle MacDonald, thanks to NZ on Air.
